{
    "clinical_study": {
        "@rank": "149510", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the safety, efficacy, quality of life and\n      predictive/selection factors for Avastin (bevacizumab) in combination with\n      carboplatin/paclitaxel  in first line in patients with advanced epithelial ovarian,\n      fallopian tube or primary peritoneal cancer in clinical practice. Data of eligible patients\n      will be collected during up to 15 months of treatment and 12 months of follow-up."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peritoneal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Peritoneal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Newly diagnosed advanced epithelial ovarian cancer, fallopian tube carcinoma or\n             primary peritoneal cancer with indication for a first-line carboplatin/paclitaxel\n             chemotherapy in combination with Avastin\n\n        Exclusion Criteria:\n\n          -  Contraindications to Avastin according to Summary of Product Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary\n        peritoneal cancer with indication for first-line carboplatin/paclitaxel chemotherapy in\n        combination with Avastin"
            }
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697488", 
            "org_study_id": "ML27765"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Offenburg", 
                    "country": "Germany", 
                    "zip": "77652"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML27765 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 27 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697488"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30/QLQ-OV28 questionnaires", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 27 months"
            }, 
            {
                "measure": "Selection criteria  for first-line treatment with Avastin and carboplatin/paclitaxel: clinical/demographic patient characteristics", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Treatment discontinuations/modifications", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Treatment duration", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}